Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received a 'Buy' rating from financial firm Rodman & Renshaw, which initiated coverage on the company with an $8.00 price target. The rating is based on the potential of Lucid-MS, the company's lead drug candidate for progressive multiple sclerosis (MS). The drug is described as a potentially first-in-class non-immunomodulatory small molecule designed to address neurodegeneration and disability progression, an area where therapeutic options remain limited.
The $8.00 price target reflects Rodman & Renshaw's valuation of Quantum BioPharma's development pipeline, with Lucid-MS at the forefront. Progressive MS, a form of the disease characterized by steady worsening of neurological function, currently lacks effective treatments that can halt or reverse disability progression. Lucid-MS is being developed to target the underlying mechanisms of the disease, offering hope for patients who have few alternatives.
Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing Lucid-MS, a patented new chemical entity that has shown in preclinical models to prevent and reverse myelin degradation—the underlying cause of MS. This mechanism of action could potentially differentiate Lucid-MS from existing immunomodulatory therapies, which primarily target inflammation rather than directly promoting myelin repair.
The initiation of coverage by Rodman & Renshaw brings increased attention to Quantum BioPharma's pipeline and the potential of Lucid-MS to fill a critical unmet need in MS treatment. For investors and industry observers, this endorsement underscores the potential value of non-immunomodulatory approaches in neurodegenerative diseases. If successful in clinical trials, Lucid-MS could offer a new avenue for treating progressive MS, potentially improving outcomes for millions of patients worldwide.
Quantum BioPharma is also known for its invention of UNBUZZD(TM), a product for alcohol misuse. The company has spun out the OTC version of UNBUZZD to Unbuzzd Wellness Inc. (UWI), led by industry veterans. Quantum retains a 19.48% ownership stake in UWI as of June 30, 2026, and is entitled to royalty payments of 7% of sales from UNBUZZD until total payments reach $250 million, after which the royalty rate drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
This dual focus on both MS and alcohol misuse disorders positions Quantum BioPharma to address significant health challenges. The 'Buy' rating from Rodman & Renshaw may increase investor confidence in the company's strategic direction and the clinical potential of its lead asset. As Lucid-MS progresses through development, its success could not only provide a new treatment option for progressive MS but also validate the company's broader approach to tackling complex neurological conditions.
For more information on Lucid-MS, visit https://nnw.fm/8uqwL.
